NTRK1 and neoplasm: A series of hybrid compounds using the tyrosine kinase receptors inhibitor lapatinib, as structural scaffold, and closo-carboranyl and metallacarboranyl moieties, as decorators, were developed as potential anti-tumor agents by dual mechanisms of action.